Toshihiro Tsukui
Overview
Explore the profile of Toshihiro Tsukui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagata M, Kozakai J, Yoshida A, Kameyama K, Oboso H, Muto H, et al.
Vet Dermatol
. 2024 Dec;
PMID: 39686904
Background: Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD). Objective: To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f...
2.
Munetomo S, Uchiyama J, Takemura-Uchiyama I, Wanganuttara T, Yamamoto Y, Tsukui T, et al.
PLoS One
. 2024 Oct;
19(10):e0310962.
PMID: 39441843
Methicillin-resistant Staphylococcus spp. present challenges in clinical and veterinary settings because effective antimicrobial agents are limited. Phage-encoded peptidoglycan-degrading enzyme, endolysin, is expected to be a novel antimicrobial agent. The enzymatic...
3.
Olivry T, Mas-Fontao A, Jacquenet S, Aumayr M, Tsukui T, Gomord V, et al.
Vet Dermatol
. 2024 Aug;
35(6):662-671.
PMID: 39210736
Background: Immunoglobulin (Ig)E cross-reactivity has been shown between Dermatophagoides farinae (Df; house dust mite) and the nematode Toxocara canis (Tc), yet its allergen basis is unknown. Objectives: To identify the...
4.
Mizuno T, Kato M, Tsukui T, Igase M
Vet Immunol Immunopathol
. 2024 Jun;
274:110792.
PMID: 38878679
Immunomodulatory antibody drugs that modulate the function of immune checkpoint molecules, such as programmed death receptor-1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been established as new cancer...
5.
Igase M, Inanaga S, Nishibori S, Itamoto K, Sunahara H, Nemoto Y, et al.
J Vet Sci
. 2024 Feb;
25(1):e15.
PMID: 38311328
Background: The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 antibody (ca-4F12-E6)...
6.
Frezza A, Lourenco M, Meira J, Tsukui T, Kageyama M, Machado L
Res Vet Sci
. 2023 Sep;
164:105002.
PMID: 37713746
Canine atopic dermatitis (CAD) is a chronic, inflammatory, and pruritic disease of the skin resulting from the loss of the epidermal barrier, sensitization, and exacerbated production of IgE antibodies mainly...
7.
Elfadadny A, Uchiyama J, Goto K, Imanishi I, Ragab R, Nageeb W, et al.
Front Vet Sci
. 2023 Aug;
10:1074127.
PMID: 37546340
The strong bond between dogs and their owners creates a close association that could result in the transfer of antibiotic-resistant bacteria from canines to humans, potentially leading to the spread...
8.
Igase M, Inanaga S, Tani K, Nakaichi M, Sakai Y, Sakurai M, et al.
Vet Comp Oncol
. 2022 May;
20(4):901-905.
PMID: 35535636
A monoclonal antibody targeting programmed cell death-1 (PD-1) is one of the most promising treatments for human cancers. Clinical studies in humans demonstrated that the anti-PD-1 antibody provides a long-lasting...
9.
Mizuno T, Takeda Y, Tsukui T, Igase M
Vet Immunol Immunopathol
. 2021 Aug;
240:110315.
PMID: 34450340
Antibody drugs are one of the most important therapeutic modalities in cancer treatment. Antibody drugs for canine cytotoxicity have been developed, and the most important way to evaluate the function...
10.
Sakai O, Ogino S, Tsukui T, Igase M, Mizuno T
J Vet Med Sci
. 2021 Aug;
83(10):1495-1499.
PMID: 34408098
Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo,...